Using TRDV1 expression in pre-treatment tumor biopsies as a proxy for intratumoral Vδ1 T cells, we found that patients with above-median expression of TRDV1 had significantly increased survival compared with those with below-median expression (Fig. 5d). The gene discussed is TRDV1; the disease is neoplasm.